We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Cancer Vaccine Collaborative Launched

By Biotechdaily staff writers
Posted on 10 Oct 2002
A research program to improve the way cancer vaccines are developed has been formed by a network of investigators from six New York (NY, USA) medical centers, who are working together as the Cancer Vaccine Collaborative (CVC) to conduct a series of early-stage clinical trials on cancer vaccines. More...
The CVC was launched at the International Cancer Immunotherapy Symposium in New York by two New York research groups: the Cancer Research Institute (www.cancerresearch.org) and the Ludwig Institute for Cancer Research (www.licr.org).

The CVC will test vaccines for several cancer types, including melanoma, sarcoma, and nonsmall cell lung, ovarian, prostate, and bladder cancers. All share the cancer/testis antigen NY-ESO-1, a special marker found almost exclusively in cancer cells. In certain tumors, the marker can become abnormally expressed, acting as a highly specific target for immune cells to attack. Although antigens alone do not elicit a strong enough response to destroy tumors, the researchers hope that vaccinating cancer patients with NY-ESO-1 can help the immune system finish the job.

The participating investigators include researchers from Columbia Presbyterian Medical Center, New York Weill Cornell Medical Center, Mount Sinai School of Medicine, Memorial Sloan-Kettering Cancer Center, and New York University Cancer Institute.

Unlike conventional vaccine trials, where data from one trial are often incomparable to data from another because of uncontrolled variables, CVC trials will use standardized tests to evaluate different ways to deliver the same vaccine agent. This methodology will allow for direct comparison with other CVC trials and show why certain vaccine strategies might result in a more robust immune response while others might not. The studies will be coordinated and conducted in parallel with each other rather than sequentially.

"Testing different vaccine strategies at one time will allow us to more quickly identify the most promising anticancer therapies,” said Dr. Eric Hoffman, director of clinical trials at the Ludwig Institute for Cancer Research. "And because all the research is done using the same methods and techniques, the Cancer Vaccine Collaborative will ensure that data from one trial site can be readily and confidently compared to that of another site.”




Related Links:
Cancer Research Institute
Ludwig Institute

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Industry experts gather at WHX Labs Dubai to discuss how leadership must adapt as AI and automation transform the laboratory (Photo courtesy of Shutterstock)

WHX Labs in Dubai spotlights leadership skills shaping next-generation laboratories

WHX Labs in Dubai (formerly Medlab Middle East), held at Dubai World Trade Centre (DWTC) from 10–13 February, brings together international experts to discuss the factors redefining laboratory leadership,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.